Defective DNA mismatch repair activity is common in sebaceous neoplasms, and may be an ineffective approach to screen for Lynch syndrome

Familial Cancer

Volumn 14, Issue 2, 2015, Pages 259-264

  Lamba, Anu R ^a   Moore, Angela Y ^b,c,d   Moore, Todd ^e   Rhees, Jennifer ^a   Arnold, Mildred A ^a   Richard Boland, C ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d Medical Center of Arlington   (United States)

^e Arlington Colorectal Clinic   (United States)

Author keywords

Lynch syndrome; Muir Torre syndrome; Sebaceous neoplasms

Indexed keywords

ADENOMA; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER SCREENING; DNA ISOLATION; EPITHELIUM TUMOR; GENE EXPRESSION; HAMARTOMA; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; ICD-9; IMMUNOHISTOCHEMISTRY; KERATOACANTHOMA; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; MICROSATELLITE MARKER; MISMATCH REPAIR; MUIR TORRE SYNDROME; PRIORITY JOURNAL; SEBACEOUS CARCINOMA; SEBACEOUS GLAND TUMOR; ADULT; AGED; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; GENETICS; MIDDLE AGED; VERY ELDERLY;

MLH1 PROTEIN, HUMAN; MSH2 PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEIN MSH2; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MISMATCH REPAIR; HUMANS; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUIR-TORRE SYNDROME; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS;

EID: 84939417462     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-015-9782-3     Document Type: Article

References (27)

1. Akhtar S, Oza KK, Khan SA, Wright J (1999) Muir-Torre syndrome: case report of a patient with concurrent jejunal and ureteral cancer and a review of the literature. J Am Acad Dermatol 41(5 Pt 1):681–686
2. Boland CR, Shike M (2010) Report from the Jerusalem workshop on Lynch syndrome-hereditary nonpolyposis colorectal cancer. Gastroenterology 138(7):2197
3. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S (1998) A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58(22):5248–5257
4. Dasgupta T, Wilson LD, Yu JB (2009) A retrospective review of 1349 cases of sebaceous carcinoma. Cancer 115(1):158–165
5. Entius MM, Keller JJ, Drillenburg P, Kuypers KC, Giardiello FM, Offerhaus GJ (2000) Microsatellite instability and expression of hMLH-1 and hMSH-2 in sebaceous gland carcinomas as markers for Muir-Torre syndrome. Clin Cancer Res 6(5):1784–1789
6. Everett JN, Raymond VM, Dandapani M, Marvin M, Kohlmann W, Chittenden A, Koeppe E, Gustafson SL, Else T, Fullen DR, Johnon RM, Syngal S, Grubre SB, Stoffel EM (2014) Screening for germline mismatch repair mutations following diagnosis of sebaceous neoplasm. JAMA Dermatol 150(12):1315–1321
7. Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Niedzwiecki D, Compton C, Mayer RJ, Goldberg R, Bertagnolli MM, Boland CR (2007) The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology 132(1):127–138
8. Goel A, Nagasaka T, Hamelin R, Boland CR (2010) An optimized pentaplex PCR for detecting DNA mismatch repair-deficient colorectal cancers. PLoS One 5(2):e9393
9. Goel A, Nagasaka T, Spiegel J, Meyer R, Lichliter WE, Boland CR (2010) Low frequency of Lynch syndrome among young patients with non-familial colorectal cancer. Clin Gastroenterol Hepatol 8(11):966–971
10. Jasperson KW, Tuohy TM, Neklason DW, Burt RW (2010) Hereditary and familial colon cancer. Gastroenterology 138(6):2044–2058
11. Kolodner RD, Hall NR, Lipford J, Kane MF, Rao MR, Morrison P, Wirth L, Finan PJ, Burn J, Chapman P (1994) Structure of the human MSH2 locus and analysis of two Muir-Torre kindreds for MSH2 mutations. Genomics 24(3):516–526
12. Kruse R, Rutten A, Schweiger N, Jakob E, Mathiak M, Propping P, Mangold E, Bisceglia M, Ruzicka T (2003) Frequency of microsatellite instability in unselected sebaceous gland neoplasias and hyperplasias. J Invest Dermatol 120(5):858–864
13. Kruse R, Ruzicka T (2004) DNA mismatch repair and the significance of a sebaceous skin tumor for visceral cancer prevention. Trends Mol Med 10(3):136–141
14. Levi Z, Hazazi R, Kedar-Barnes I, Hodak E, Gal E, Mor E, Niv Y, Winkler J (2007) Switching from tacrolimus to sirolimus halts the appearance of new sebaceous neoplasms in Muir-Torre syndrome. Am J Transplant 7(2):476–479
15. Lynch HT, Lynch PM, Pester J, Fusaro RM (1981) The cancer family syndrome. Rare cutaneous phenotypic linkage of Torre’s syndrome. Arch Intern Med 141(5):607–611
16. Machin P, Catasus L, Pons C, Munoz J, Conde-Zurita JM, Balmana J, Barnadas M, Marti RM, Prat J, Matias-Guiu X (2002) Microsatellite instability and immunostaining for MSH-2 and MLH-1 in cutaneous and internal tumors from patients with the Muir-Torre syndrome. J Cutan Pathol 29(7):415–420
17. Muir EG, Bell AJ, Barlow KA (1967) Multiple primary carcinomata of the colon, duodenum, and larynx associated with kerato-acanthomata of the face. Br J Surg 54(3):191–195
18. Orta L, Klimstra DS, Qin J, Mecca P, Tang LH, Busam KJ, Shia J (2009) Towards identification of hereditary DNA mismatch repair deficiency: sebaceous neoplasm warrants routine immunohistochemical screening regardless of patient’s age or other clinical characteristics. Am J Surg Pathol 33(6):934–944
19. Plocharczyk EF, Frankel WL, Hampel H, Peters SB (2013) Mismatch repair protein deficiency is common in sebaceous neoplasms and suggests the importance of screening for Lynch syndrome. Am J Dermatopathol 35(2):191–195
20. Ponti G, de Ponz LM (2005) Muir-Torre syndrome. Lancet Oncol 6(12):980–987
21. Popnikolov NK, Gatalica Z, Colome-Grimmer MI, Sanchez RL (2003) Loss of mismatch repair proteins in sebaceous gland tumors. J Cutan Pathol 30(3):178–184
22. Schwartz RA, Torre DP (1995) The Muir-Torre syndrome: a 25-year retrospect. J Am Acad Dermatol 33(1):90–104
23. South CD, Hampel H, Comeras I, Westman JA, Frankel WL, de la Chapelle A (2008) The frequency of Muir-Torre syndrome among Lynch syndrome families. J Natl Cancer Inst 100(4):277–281
24. Torre D (1968) Multiple sebaceous tumors. Arch Dermatol 98(5):549–551
25. Vasen HF (2005) Clinical description of the Lynch syndrome [hereditary nonpolyposis colorectal cancer (HNPCC)]. Fam Cancer 4(3):219–225
26. Vasen HF, Moslein G, Alonso A, Bernstein I, Bertario L, Blanco I, Burn J, Capella G, Engel C, Frayling I, Friedl W, Hes FJ, Hodgson S, Mecklin JP, Moller P, Nagengast F, Parc Y, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Wijnen J (2007) Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 44(6):353–362
27. Roberts ME, Riegert-Johnson DL, Thomas BC, Thomas CS, Heckman MG, Krishna M, DiCaudo DJ, Bridges AG, Hunt KS, Rumilla KM, Cappel MA (2013) Screening for Muir-Torre syndrome using mismatch repair protein immunohistochemistry of sebaceous neoplasms. J Genet Couns 22(3):393–405